Rebar R W, Zeserson K
University of Cincinnati Medical Center, Department of Obstetrics and Gynecology, Ohio 45267-0526.
Contraception. 1991 Jul;44(1):1-10. doi: 10.1016/0010-7824(91)90101-k.
This review details the characteristic features of three new progestogens which soon will be available in low-dose combination oral contraceptive agents in the United States. Available data suggest that desogestrel, gestodene, and norgestimate are extremely potent progestogens with few androgenic side effects. The smaller changes in lipids induced by these progestogens seem to confer some advantage to the use of preparations containing one of these agents. Whether this advantage is also present clinically remains to be determined.
本综述详细介绍了三种新型孕激素的特征,这三种孕激素很快将在美国以低剂量复方口服避孕药的形式上市。现有数据表明,去氧孕烯、孕二烯酮和诺孕酯是强效孕激素,几乎没有雄激素副作用。这些孕激素引起的血脂变化较小,这似乎为使用含有其中一种药物的制剂带来了一些优势。这种优势在临床上是否也存在仍有待确定。